A Science and Technology Blog
Of the many mutations found in the variant, the scientists have pointed out that the N501Y mutation increases the transmissibility of the variant in humans. Though no studies have so…
The greatly reassuring decision to seek additional safety and immunogenicity data from the Pune-based Serum Institute of India and Hyderabad’s Bharat Biotech underlines the regulator’s priorities even for emergency use…
Unlike Pfizer, AstraZeneca, which is carrying out the phase-3 trials of the Oxford vaccine in four countries, is yet to secure a nod from any of the regulatory agencies despite…
According to the release, the Phase-3 trial has exceeded two months of median follow-up post vaccination as required by the U.S. FDA for the purpose of Emergency Use Authorization (EUA). While the…
Two doses of the vaccine given in two different regimen showed different efficacies. In the case of the regimen (involving 2,741 participants) where a halved dose was used as a…
Offering the vaccine right away to those in the placebo group will first require unblinding the study. Unblinding the study and offering the vaccine to the placebo group will make it almost impossible to gather further information on vaccine efficacy, thus making full licensure challenging.
On November 18, Pfizer announced that the final efficacy analysis of its candidate mRNA-based vaccine (BNT162b2) in phase-3 trial has been completed and the vaccine shows 95% efficacy to prevent…
The interim results of Moderna’s mRNA vaccine show that the vaccine has 94.5% efficacy in preventing COVID-19. The interim analysis, which was based on 95 cases, found that 90 participants…
